Kaltura (NASDAQ:KLTR – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Kaltura has set its Q3 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.
Kaltura (NASDAQ:KLTR – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $44.03 million for the quarter, compared to the consensus estimate of $43.27 million. Kaltura had a negative net margin of 24.82% and a negative return on equity of 155.01%. On average, analysts expect Kaltura to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Kaltura Stock Performance
Shares of KLTR opened at $1.34 on Tuesday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 1.10 and a current ratio of 1.10. The company has a market capitalization of $199.65 million, a price-to-earnings ratio of -4.19 and a beta of 0.75. The company’s 50 day simple moving average is $1.29 and its 200 day simple moving average is $1.23. Kaltura has a 1 year low of $0.76 and a 1 year high of $2.03.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Kaltura
About Kaltura
Kaltura, Inc provides various software-as-a-service (SaaS) products and solutions and a platform-as-a-service (PaaS) in the United States, Europe, the Middle East, Africa, and internationally. The company operates through two segments, Enterprise, Education, and Technology (EE&T); and Media and Telecom (M&T).
Featured Articles
- Five stocks we like better than Kaltura
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Intel: Is Now the Time to Be Brave?
- Dividend Payout Ratio Calculator
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is the Australian Securities Exchange (ASX)
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Kaltura Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaltura and related companies with MarketBeat.com's FREE daily email newsletter.